Drugs / COVID-19 mRNA vaccine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Comirnaty | — | 2020-12-21 | europa.eu ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05144139 | Dec 2021 → Aug 2022 | COVID-19 | Stemirna Therapeutics | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04878211 | Jun 2021 → Apr 2023 | multiple sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07655180 Comparator | Jun → Aug 2026 overdue | COVID-19 | Invivyd, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 mRNA vaccine | “Participants received non-live COVID-19 mRNA vaccine at least two weeks prior to start of ofatumumab (OMB157) (20 mg subcutaneous).” NCT04878211 ↗ |
| Modality | Vaccine | “Pfizer or Moderna mRNA Vaccine” NCT04878211 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT05144139 ↗ |